Kornimate/medical-research-clean huggingface dataset:
stool sampling in the acute isolated patient , efficient acquiring with a novel device

Conditions: Feasibility Study

Summary: stool sample device tested on patients admitted to oncological dept. with diarrhea, in order to shorten time in isolation and time to relevant treatment.

the stool sample device will be tested on all patients admitted to an oncological dept. on zealand university hospital, with diarrhea, in order to examine if the the device is able to shorten time in isolation and time to relevant treatment.

Eligibility criteria:
inclusion criteria: * understanding danish * admitted to dept og oncology with diarrhea * cognitive intact * co operable to fecal sampling exclusion criteria: * expected survival less than 2 weeks
induction chemotherapy with gemcitabine and cisplatin followed by ccrt for unresectable pancreatic carcinoma

Conditions: Pancreatic Carcinoma Non-resectable

Summary: this phase ii trial chose the induction chemotherapy with gemcitabine and cisplatin followed by chemoradiotherapy (crt) with gemcitabine to optimize the treatment for pancreas cancer patients with locally advanced disease and the purpose of this trial is to evaluate the efficacy of induction ct with gemcitabine and cisplatin followed by crt for unresectable pancreatic carcinoma.

the primary endpoint is feasibility and compliance of induction chemotherapy with gemcitabine and cisplatin followed by crt for locally advanced unresectable pancreatic cancer. previous studies showed that approximately 20% of patients with locally advanced disease developed the early distant metastasis.\[6, 7\] thus, it will be expected that at least 80% of total patients will be eligible for induction chemotherapy after completion of induction chemotherapy. an experimental arm that result a compliance of 80% would merit further study. if the true compliance rate of the patients who will eligible for crt is ≤ 60%, null hypothesis will be rejected with a power of 80% and a type i error of 5%. thus, the required number of evaluable patients is 24. considering the 10% follow-up loss and 20% distant metastasis rate after induction chemotherapy, a total of 34 eligible patients will be enrolled.

Eligibility criteria:
inclusion criteria: * pathologically confirmed adenocarcinoma of the pancreas * unresectable locally advanced disease base on institutional standard criteria of unresectability disease following radical surgery. there is no evidence of metastatic disease in the major viscera and no peritoneal seeding * patients with biliary or gastroduodenal obstruction must have drainage prior to starting chemoradiation * all malignant disease must be encompassable within a single irradiation field (15x15cm maximum) * all patients must have radiographically assessable disease * no previous irradiation to the planned field * age of ≥ 18 years * performance status of 0 to 1 on the eastern cooperative oncology group (ecog) score * required entry laboratory parameters wbc count ≥ 1,000/mm3; hemoglobin level ≥ 7.5 g/dl; platelet count ≥ 100,000/mm3; total bilirubin ≤ 3.0 mg/dl (patients with elevated bilirubin due to obstruction should be stented and their bilirubin should be decrease ≤ 3.0 mg/dl prior to study entry); creatinine ≤ 3.0 mg/dl * oral intake (including j-tube feeding) of ≥ 1,500 calories/day should be maintained. * signed informed consent form prior to study entry exclusion criteria: * there is evidence of metastasis in the major viscera or peritoneal seeding. * age of \< 18 years * previous history of rt adjacent to planned field * poor performance status of 2 to 4 on the eastern cooperative oncology group (ecog) score * pregnant or breast feeding status * previous history of uncontrolled other malignancies within 2 years
evaluating dynamic arterial elastance in septic shock patients.

Conditions: Septic Shock

Summary: assess the effectiveness and safety of using dynamic arterial elastance as a tool for weaning vasopressor support in patients with septic shock, compared to a control group

an open-label, randomized controlled clinical trial will be conducted with two patient groups. our hypothesis is that using dynamic arterial elastance (eadyn) as a tool to guide vasopressor weaning can reduce the duration of vasopressor support. eligible patients will be randomly assigned to either the eadyn weaning arm or the mean arterial pressure (map) weaning arm in a 1:1 ratio. blinding of participants and investigators will not be possible due to the study's methodology. the analysis will be conducted on an intention-to-treat basis.

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age. * admission to the icu. * septic shock defined according to the third international consensus definitions for sepsis and septic shock (sepsis-3). * hypotension requiring vasopressor support to maintain a map ≥ 65 mmhg. * sofa score ≥ 4. * vasopressor support duration ≥ 4 hours. * patients requiring mechanical ventilation. * patients who have reached the hemodynamic stabilization phase and are ready to begin the vasopressor weaning process with norepinephrine, defined as: mean arterial pressure (map) \> 75 mmhg, cardiac index (ci) \> 2.5 l/min/m², and lactate level \< 2 mmol/l. exclusion criteria: * pregnant individuals. * hemodynamic instability due to cardiac arrhythmias. * hepatic cirrhosis. * kidney or liver transplant. * high probability of mortality within 24 hours, according to medical judgment. * left ventricular ejection fraction (lvef) less than 50%. * right ventricular dysfunction, defined as a tapse (tricuspid annular plane systolic excursion) measurement of less than 1.6 cm. * patients spontaneously breathing.

Keywords: dynamic arterial elastance (eadyn). vasopressor weaning. septic shock.
symptomatic trigeminal neuralgia attributed to multiple sclerosis - a prospective study in 60 patients

Conditions: Trigeminal Neuralgia; Multiple Sclerosis; Pain, Neuropathic

Summary: clinical characteristics, neuroanatomical findings and efficacy of medical and surgical treatment of symptomatic trigeminal neuralgia - a systematic prospective study of 60 consecutive patients

background among patients with tn, approximately 15% has secondary tn caused by another underlying condition such as multiple sclerosis or a tumor. studies of classical tn patients have shown a strong association between a severe nvc of the trigeminal nerve and the painful side. this association has been less investigated in stn. there are no previous systemic and prospective studies of the underlying causes, characteristics and treatment response of patients with stn. most existing studies on stn have various methodological drawbacks as inclusion was not prospective, diagnosis was not consistent with international guidelines, imaging techniques were not adequately advanced at the time of publication and evaluation of treatment efficacy was not performed by evaluators independent of the neurosurgeon. aims 1) to describe the clinical characteristics, the neuroanatomical findings using 3.0 tesla mri, and the efficacy of medical and surgical treatment in stn hypotheses 1. in stn, there is a correlation between demylinating brainstem plaques and presence and degree of neurovascular contact of the trigeminal nerve ipsilateral to the painful side 2. the efficacy of medical and surgical treatment of stn is comparable to the efficacy in patients with classical trigeminal neuralgia power calculations sample size depends on the number of patients in the inclusion period. the estimated number of included patients is at least 60 patients. methods data have been collected prospectively since 2012 based on semi-structured interview forms completed at out-patient visits at the danish headache center. the efficacy of medical and surgical treatment was also documented prospectively by structured interviews. efficacy of surgical treatment was evaluated by independent assessors. all patients had a 3.0 tesla mri with a special protocol adapted for the trigeminal nerve and the brainstem. ethical considerations the treatment of patients with stn will not differ from the usual treatment and decision-taking.

Eligibility criteria:
inclusion criteria: * diagnosis of secondary trigeminal neuralgia attributed to multiple sclerosis
omega 3 in intervention spinal cord injured people

Conditions: Lipid Metabolism Disorders; Peroxidase; Defect

Summary: the objective of this study is to evaluate the effect of omega 3 fatty acid on neurological recovery, lipid profile and antioxidant system in patients with spinal cord injury. one hundred spinal cord injured patients who come to clinic of spinal injury repair research center selected. then the patients will receive two supplements capsules of omega 3 (600 mg) in the intervention group and placebo in the control group. primary outcome measures are professionals evaluation of neurological function by using : * asia scale for sensory and motor function * fim scale for functional potential * fam * sf_36 for quality of life lipid profile and antioxidant profile evaluation by using: * fbs * 2hpp * insulin * ldl * total chol * tg * hdl * leptin adiponectin -calcium- * 25ohd * pth,lh, fsh, prolactin,testosterone in males bone markers by serum levels of :osteocalcin-osteoprotegrin_bone specified alp- ctx - rankl * bmd

all no neurological evaluation will be done by experiment researcher under considering of a neurologist.all sub clinical evaluation will be done by specific, sensitive and valid laboratory methods. intervention time will be 14 months.comparison of these variables will be done before and after intervention.

Eligibility criteria:
inclusion criteria: no metabolic, malignant or kidney disorder, normal tsh, lh, fsh, prolactin, and testosterone in men and normal prolactin, estradiol, lh, fsh, and tsh in women exclusion criteria: * pregnancy, lactation, presence of bone disease,hypersensitivity to fish or fish oil, hypertension

Keywords: spinal,, bone, cord injury, lipid,antioxidant
observational study of pain reduction in late-stage cancer patients who are receiving low-dose chemotherapy

Conditions: Acute Pain

Summary: observational study of pain reduction in late stage cancer patients receiving low-dose chemotherapy

observational study of pain reduction in late stage cancer patients who are receiving low-dose chemotherapy (metabolic targeting)

Eligibility criteria:
inclusion criteria: * patient requests to be included in this study exclusion criteria: * patient does not request to be included in this study
a study on behavioral and psychological symptoms of dementia

Conditions: Dementia

Summary: the purpose of this observational study is to obtain the current status of patients with behavioral and psychological symptoms of dementia. this study is also expected to further provide insight into the evolution of behavioral and psychotic symptoms and its relationship with treatment as well as severity of cognitive declines in a naturalistic setting.

this is an observational, prospective, multi-center study to obtain information about the symptoms and treatment received for patients with behavioral and psychological symptoms of dementia (bpsd). patients must first meet eligibility criteria and sign informed consent. patient treatment will be based upon investigator opinion. the following parameters will be assessed: patient's characteristics, clinical global impression (cgi) score, neuropsychiatric inventory (npi), and minimal mental status examination (mmse). each patient will be observed for 12 weeks. medication dosing regimen will be flexible throughout the study and is based on patient response and investigator judgment. during the study observation period, all patients will attend clinic visits for the subsequent 12 weeks (visit 2 to 3) as is the usual clinical practice. patients can visit clinics on additional dates as needed or by request. at the pre-planned clinic visits, cgi score, npi, vital signs, reports of adverse events, drug information, and mmse score (visit 3) will be recorded. this is an observational study and no study drug is administered.

Eligibility criteria:
inclusion criteria: * patients with the diagnosis of dementia according to dsm-iv (diagnostic and statistical manual of mental disorders, fourth edition) criteria * patients meet one of the following types of dementia: dementia of the alzheimer's type (ad), vascular dementia (vad), dementia of lewy body (dlb), parkinson's disease dementia (pdd) * patients have one or more active symptoms of behavioral and psychological symptoms of dementia (bpsd) on neuropsychiatric inventory (npi) and have not received treatment with antipsychotics, mood stabilizers, or antidepressants within 1 month prior to study entry * patients are with caregiver(s) who can give appropriate information about the patients and can assist with the assessment during the study * patients (or a legally acceptable representative) have signed the informed consent form exclusion criteria: * patients with concurrent other primary major psychiatric disorders (such as schizophrenia or bipolar disorder) * patients with history of severe allergies or multiple adverse drug reactions * patients with history or current symptoms of tardive dyskinesia * patients with history of neuroleptic malignant syndrome (nms) * patients who participated in a clinical trial of any investigational drug within 1 month (30 days) prior to study entry

Keywords: behavioral and psychological symptoms of dementia bpsd npi cgi mmse
use of a novel fibrin sealant in total knee arthroplasty

Conditions: Osteoarthritis; Intraoperative Bleeding

Summary: applying a fibrin spray, after knee device implantation, will help in reducing patient blood loss and decrease the drop in both hemoglobin and hematocrit levels. also, with decreased blood loss there should be a reduced need for blood transfusions.

study design study design and control methods: this study is designed as a prospective, randomized, double-blinded controlled clinical trial to compare the effect of a fibrin spray applied to the surgical wound as compared to patients not receiving the fibrin spray. treatment group: the subjects will be randomly assigned to the fibrin treatment group or to the control group at the time of the surgery via the opening of a randomly selected sealed envelope. the patient and the independent reviewer will be blinded as to which treatment group the patient is assigned to. this information will be linked to a confidential database for later review by the principal investigator. treatment allocation: all eligible patients (i.e., meeting inclusion criteria and no exclusion criteria) will be treated and observed per the research protocol. all patients will maintain the right to refuse participation and receive a specific treatment of the study if desired. trial population: the target sample size is 70 patients for both the treatment and control groups (140 total) with each group split evenly between males and females. there will be one actively enrolling surgeon (dr. brett levine). the goal is to enroll a total of 140 subjects experiencing joint pain that warrants a total knee arthroplasty (tka). the specific diagnosis for the joint pain will not direct the subjects' assignment or eligibility at the time of surgery. all 140 patients will be enrolled from the office of the primary investigator (dr. brett levine). all indications for tka will be included unless one of the exclusion criteria is met.

Eligibility criteria:
inclusion criteria: * patients must be male or female of any race * ages 18-80 years old * patients must be undergoing an elective, primary knee arthroplasty performed by the principal investigator exclusion criteria: * allergy or intolerance to the study materials * surgical intervention during the past month for the treatment of the painful joint or its underlying etiology * history of previous surgeries on the affected joint including previous arthroscopy (open surgeries) * women that are pregnant or may become pregnant * patient declines to participate

Keywords: blood loss hemoglobin hematocrit blood transfusions
safety of human embryonic stem cell (hesc)-derived mesenchymal stem cells in interstitial cystitis

Conditions: Interstitial Cystitis; Stem Cell Transplant; Mesenchymal Stem Cell

Summary: this study primarily aimed to evaluate the safety of human embryonic stem cell (hesc)-derived mesenchyma stem cells in interstitial cystitis.


Eligibility criteria:
inclusion criteria: * female, aged \>= 20 years * interstitial cystitis symptom duration more than 6 months * presence of hunner lesions in outpatient cystoscopy (within one months of screening), with size \< 2cm, number \<= 2 * vas (visual pain analogue scale) \>=4 in screening symptom questionnaire * those who are suitable for stem cell transplantation * normal laboratory findings (hematological, chemical) * no history of drug abuse * negative hiv, hbv, hcv serology tests * no history of malignancies * willing to contraception * no plan for blood, tissue donation * who can understand consent form and willing to participate in the study exclusion criteria: * recurrent urinary tract infection ( more than twice per past six months or more than three times per past one year) or active urinary tract infection * any active or past history of tuberculosis or systemic infection * anatomical abnormality of lower urinary tract * history of following procedures * stem cell transplantation in past 6 months, * transurethral resection/fulguration of hunner lesion or hydrodistension of bladder * intravesical instillation of ialuril * hysterectomy, anti-incontinence surgery, transvaginal surgery, pelvic organ prolapse repair, vagina delivery or c/sec * any neurological conditions including cerebrovascular disease, multiple sclerosis, spinal cord injury, parkinson disease * indwelling foley catheter or intermittent catheterization * any plans for electrostimulation, neuromodulation, physiotherapy or operation for other organs * any history of malignancy * history of myocardiac infarction in past 12 months * uncontrolled diabetes (hbalc \>= 7.2%) or diabetes requiring insulin injection * uncontrolled hypertension (systolic \>170mmhg or \ 100mmhg or \<50mmhg) * immunodeficiency * positive hbv, hcv, hiv, syphilis * pregnant or on breast feeding * any history of drug, alcohol abuse. mis-use * any significant signs, symptoms or previous diagnosis of psychological disorder * impossible to follow scheduled visits * currently participating or participated in other clinical studies within past 3 months * allergic to protein products (serum), antibiotics (gentamicin), dmso (dimethyl sulfoxide) * any circumstances that is not suitable for participating or continuing clinical study or participants who clinical investigator considers not suitable for participation
drinking effect of electrolyzed alkaline reduced water on functional constipation

Conditions: Chronic Constipation

Summary: the goal of this clinical trial is to investigate drinking effect of electrolyzed hydrogen-rich alkaline reduced water (eharw) in chronic constipation patients. the main question is that drinking eharw will improve the symptoms of chronic constipation for 4 weeks. participants will drink eharw (20 ml/kg of body weight/day) generated from the experimental device for 4 weeks.

patients diagnosed with constipation will be recruited and screened according to the inclusion and exclusion criteria after sign in the informed consent form. the selected patients will be enrolled. the experimental device (btm-1200, bion-tech, gyeonggi-do, korea) will be installed at each patient's house. the researcher will instruct patients drinking method. the patients will drink a total of 20 ml/kg of body weight/day of eharw (ph 9.5) in 3-different times, and drink directly from the device on an empty stomach for 4 weeks. the clinical trial is conducted in a single group without a control group, and the efficacy is evaluated by comparing the symptoms of constipation pre- and post-intervention. the primary outcome is the proportion of responders based on frequency of complete complete spontaneous bowel movement (csbm).

Eligibility criteria:
inclusion criteria: * men and women aged 19 to 70 years old * those who meet the criteria for roma ⅳ function constipation * symptoms begin before 6 months and last for more than 3 months * those who do not have organic lesions that may cause constipation * a patient who has personally signed the consent form * if all the criteria meet exclusion criteria: * those taking drugs such as opioid analgesics, antipsychotics, calcium blockers, and parasympathetic antagonists * kidney disease (renal failure, potassium excretion disorder, etc.) * patients with colon-related diseases (colon cancer, intestinal stenosis, rectal flow, anal fissure, rectal bleeding), diabetes, thyroid dysfunction, or anemia * pregnant or lactating women * in addition to the above, those who are judged to be difficult to conduct research by the clinical trial director * excluded if at least one of the above criteria meet

Keywords: constipation hydrogen-rich alkaline ionized water complete spontaneous bowel movement patient assessment of constipation-symptoms patient assessment of constipation-quality of life
study of root coverage with acellular dermal matrix: puros® dermis versus alloderm®

Conditions: Gingival Recession

Summary: the purpose of the study is to evaluate whether clinical parameters for puros dermis are, at minimum, equivalent when compared to alloderm, the current industry standard, for the treatment of single, non-adjacent miller's class i or ii gingival recession.

this is a prospective, post-market, randomized, examiner-only masked multi-center study to evaluate whether clinical parameters for puros dermis are at minimum, equivalent when compared to alloderm, the current industry standard for the treatment of single, non-adjacent miller's class i or ii gingival recession.

Eligibility criteria:
inclusion criteria: * male or female, of any ethnicity, between 18 and 99 years of age. * no known allergies to study material. * able to communicate with the investigator and read, understand, and sign the informed consent form. * maxillary incisor, canine, or premolar with at least one miller's class i or ii gingival recession defects that are not adjacent to one another. * depth of the gingival recession defects of 2mm or greater. * no gingival surgery within the past 12 months at the defect site. no prior antibiotic use within 3 months with less than 2 weeks durations. * ability to maintain good oral hygiene. exclusion criteria: * patients taking any medications known to cause gingival enlargement. * patients with unstable systemic diseases. * patients with compromised immune systems or unstable bleeding disorders. * patients with active infectious diseases (e.g. hepatitis, tuberculosis, hiv, etc.). * patients with a mental disability that may hinder participation in the study (e.g. inability to follow through with oral hygiene instructions, postoperative instructions, follow-up commitments, etc.). * patients taking steroid medications. * tobacco use or smoking within 1 year of screening visit (e.g. cigarettes, pipes, cigars, chew). * pregnant females or females attempting to get pregnant. * other conditions the investigator feels would inhibit from a good candidate for the study.

Keywords: exposed root surface or tooth tooth sensitivity miller class i miller class ii gingival margin